<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>3. Kernicterus and Clinical Features</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="02-pathological-jaundice.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 75%;"></div>
                        </div>
                       <span class="progress-text">Lecture 3 of 4</span>
                    </div>
                    <a href="04-management-and-treatment.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Kernicterus and Clinical Features</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="clinical-features" class="content-section" aria-labelledby="section-heading-23">
                    <h2 id="section-heading-23" class="section-heading">
                        <span class="heading-icon"> </span>
                        <span class="heading-text">Clinical features</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Jaundice may be present at birth or may appear at any time during the neonatal period, depending on etiology.</li>
                            <li>Jaundice usually becomes apparent in a cephalocaudal progression, starting on the face and progressing to the abdomen and then feet, as serum levels increase.</li>
                            <li>Dermal pressure may reveal the anatomic progression of jaundice (face, $=5 \mathrm{mg} / \mathrm{dL}$; mid-abdomen, $=15 \mathrm{mg} / \mathrm{dL}$ soles, $=20 \mathrm{mg} / \mathrm{dL}$</li>
                            <li>clinical examination cannot be depended on to estimate serum levels.</li>
                        </ul>
                        <p>Whereas jaundice from deposition of indirect bilirubin in the skin tends to appear bright yellow or orange, jaundice of the obstructive type (direct bilirubin) has a greenish or muddy yellow cast.</p>
                        <p>signs of kernicterus rarely appear on the 1st day</p>
                        <ul>
                            <li>affected infants may present with lethargy and poor feeding</li>
                            <li>without treatment, can progress to acute bilirubin encephalopathy</li>
                        </ul>
                        <p><strong>Laboratory Evaluation of the Jaundiced Infant of 35 or More Weeks' Gestation</strong></p>
                        <ul>
                            <li>Jaundice in first 24 hr</li>
                            <li>Measure TcB and/or TSB</li>
                            <li>Jaundice appears excessive for infant's age</li>
                            <li>Measure TcB and/or TSB</li>
                            <li>Infant receiving phototherapy or TSB rising rapidly and unexplained by history and physical examination
                                <ul>
                                    <li>Blood type and Coombs test,</li>
                                    <li>Complete blood count and smear</li>
                                    <li>Measure direct or conjugated bilirubin</li>
                                    <li>It is an option to perform reticulocyte count</li>
                                    <li>Repeat TSB in 4-24 hr depending on infant's age and TSB level</li>
                                </ul>
                            </li>
                            <li>TSB concentration approaching exchange levels or not responding to phototherapy
                                <ul>
                                    <li>Perform reticulocyte count,</li>
                                    <li>G6PD</li>
                                    <li>albumin</li>
                                </ul>
                            </li>
                            <li>Elevated direct (or conjugated) bilirubin level
                                <ul>
                                    <li>Do urinalysis</li>
                                    <li>urine culture.</li>
                                    <li>Evaluate for sepsis if indicated by history and physical examination</li>
                                </ul>
                            </li>
                            <li>Jaundice present at or beyond age 3 wk , or sick infant
                                <ul>
                                    <li>Total and direct (or conjugated) bilirubin level</li>
                                    <li>If direct bilirubin elevated, evaluate for causes of cholestasis</li>
                                    <li>Check results of newborn thyroid and galactosemia screen</li>
                                    <li>evaluate infant for signs or symptoms of hypothyroidism</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>

                <section id="kernicterus" class="content-section" aria-labelledby="section-heading-24">
                    <h2 id="section-heading-24" class="section-heading">
                        <span class="heading-icon"> </span>
                        <span class="heading-text">Kernicterus</span>
                    </h2>
                    <div class="content-card">
                        <h3>DEFINITION</h3>
                        <ul>
                            <li>Neurological syndrome resulting deposition of unconjugated bilirubin in the basal ganglia and brainstem nuclei</li>
                            <li>Kernicterus $\equiv$ Bilirubin encephalopathy</li>
                            <li>pathogenesis
                                <ul>
                                    <li>multifactorial</li>
                                    <li>involves an interaction between</li>
                                    <li>unconjugated bilirubin levels,</li>
                                    <li>albumin binding</li>
                                    <li>unbound bilirubin levels</li>
                                    <li>passage across the blood-brain barrier,</li>
                                    <li>neuronal susceptibility to injury.</li>
                                </ul>
                            </li>
                        </ul>
                        <h3>Pathogenesis</h3>
                        <p>Multifactorial involvement</p>
                        <img src="../assets/images/2025_09_02_1bc465bb9c73bf4afa7cg-063-1.jpg" alt="Flowchart showing the multifactorial pathogenesis of kernicterus, involving bilirubin production, binding, and blood-brain barrier passage." class="content-image">
                        <p><strong>Bilirubin toxicity-</strong></p>
                        <ul>
                            <li>Factors that Increases permeability of BBB or nerve cell membranes to bilirubin or</li>
                            <li>Disruption of the blood-brain barrier
                                <ol>
                                    <li>Asphyxia</li>
                                    <li>Prematurity</li>
                                    <li>Hyperosmolality</li>
                                    <li>Infection</li>
                                </ol>
                            </li>
                        </ul>
                        <h3>Mechanism of toxicity</h3>
                        <ul>
                            <li>Unclear but several postulations
                                <ol>
                                    <li>Inhibits mitochondrial enzymes interfering with DNA synthesis</li>
                                    <li>Induces DNA strand breakage</li>
                                    <li>Inhibits protein synthesis and phosphorylation</li>
                                </ol>
                            </li>
                        </ul>
                        <h3>Critical levels</h3>
                        <ul>
                            <li>Precise level of the bilirubin at which Kernicterus occurs unknown</li>
                            <li>Encephalopathy develops $>30 \mathrm{mg} / \mathrm{dL}$ in term healthy infants without hemolysis (21-50 $\mathrm{mg} / \mathrm{dL}$)</li>
                            <li>All infants with hemolysis have risk directly proportional to the serum bilirubin levels</li>
                            <li>VLBW infants $8-12 \mathrm{mg} / \mathrm{dL}$ associated with Kernicterus</li>
                            <li>The less mature the infant the greater the susceptibility to Kernicterus</li>
                        </ul>
                        <h3>Clinical forms</h3>
                        <p>signs and symptoms usually appear 2-5 days after birth in term infants and as late as $7^{\text {th}}$ day in premature</p>
                        <p>Early sign not indistiguishable from</p>
                        <ul>
                            <li>Sepsis</li>
                            <li>asphyxia</li>
                            <li>hypoglycemia</li>
                            <li>intracranial hemorrhage</li>
                        </ul>
                        <p><strong>Acute form - 3 phases</strong></p>
                        <ol>
                            <li>Phase 1-1-2days;
                                <ul>
                                    <li>poor suckling;</li>
                                    <li>$\downarrow$ mororeflex+deep tendon reflexes;</li>
                                    <li>lethargy;seizures;</li>
                                    <li>respiratory distress</li>
                                    <li>stupor</li>
                                </ul>
                            </li>
                            <li>Phase 2-mid 1st $\mathrm{wk}-$
                                <ul>
                                    <li>hypertonia of extensor muscles</li>
                                    <li>opisthotonous</li>
                                    <li>bulging fonatnelles</li>
                                    <li>high pitched cry</li>
                                    <li>Twitching</li>
                                </ul>
                            </li>
                            <li>Phase 3-after wk1-
                                <ul>
                                    <li>hypertonia</li>
                                    <li>Spasms</li>
                                    <li>Convulsions</li>
                                    <li>posturing</li>
                                </ul>
                            </li>
                        </ol>
                        <p><strong>Chronic form</strong></p>
                        <ul>
                            <li>Year 1-opisthotonus;
                                <ul>
                                    <li>hypertonia;</li>
                                    <li>active deep tendon reflexes;</li>
                                    <li>obligatory tonic neck reflexes;</li>
                                    <li>delayed motor skills;</li>
                                    <li>rigidity and convulsion</li>
                                </ul>
                            </li>
                            <li>After year 2-movt disorders e.g.
                                <ul>
                                    <li>bilateral choreoathetosis;</li>
                                    <li>ballismus;</li>
                                    <li>tremors</li>
                                    <li>Seizures</li>
                                    <li>mental deficiency;</li>
                                    <li>disarthric speech;</li>
                                    <li>sensorineural hearing loss;</li>
                                    <li>upward gaze abnormalities</li>
                                </ul>
                            </li>
                        </ul>
                        <h3>Pathology</h3>
                        <p>Generalized yellow staining of the brain which later localizes to:-</p>
                        <ol>
                            <li>Corpus subthalamicum</li>
                            <li>Hippocampus</li>
                            <li>Olfactory area</li>
                            <li>Striate bodies</li>
                            <li>Thalamus</li>
                            <li>Globus pallidus</li>
                            <li>Inferior clivus</li>
                            <li>Putamen</li>
                            <li>Cerebellar and cranial nerve nuclei</li>
                        </ol>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="02-pathological-jaundice.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 75%;"></div>
                        </div>
                       <span class="progress-text">Lecture 3 of 4</span>
                    </div>
                    <a href="04-management-and-treatment.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>```
